Biologics are the genetically engineered proteins derived from human genes. These are composed of sugars, proteins or nucleic acids or complex combination of these substances. The biologic drugs are derived from a variety of natural sources such as humans, animals, or microorganisms. These drugs are widely used in the treatment of rheumatoid arthritis, anemia, cancer, and other diseases. The products offered by the global biologics market include vaccines, blood and blood components, allergenics, somatic cells gene therapy, tissues, and recombinant therapeutic proteins.
Rise in incidences of chronic diseases, loss of patent extensions of branded drugs, and the increased availability of advanced diagnostics is expected to boost the growth of biologics market. In addition, growth in technology for the production of biologics is projected to fuel the market growth. However, difficulty in manufacturing biologic drugs and the process involved in maintenance, which includes preventing from environmental contamination, maintaining refrigeration processes, and others hinder the market. The increase in demand for advanced diagnostics in treatment purposes and the loss of patent extensions of branded drugs provide opportunity for the growth of global biologics market.
The market is segmented based on product type, therapeutics, source of material, and geography. Based on product type, it is divided into monoclonal antibodies (MAbs), hormones, growth factors, fusion proteins, cytokines, therapeutic enzymes, blood factors and anticoagulants, vaccines, blood and blood products, allergenic extracts, human cells and tissues, proteins, gene therapies, cellular therapies, and xenotransplantation products. The market on the basis of therapeutics is classified into oncology, cardiovascular, immunological diseases, infectious diseases, and metabolic diseases. By source material, it is categorized into humans, avian cell culture, yeast, bacteria, insects cell culture, and transgenics. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players in the global biologics market include F. Hoffmann-La Roche AG, Sanofi, Eli Lilly & Company, GSK Biologicals SA, Becton, Dickinson & Company, AstraZeneca plc, Bayer AG, Pfizer Inc, Novartis AG, and Merck KGaA.
Key Benefits :
- The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided, which elucidates the prevailing opportunities.
- Key players are profiled and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the market.
- Extensive analysis by product elucidates the use of biologics drugs for the treatment of rheumatoid arthritis and other chronic illnesses.
Biologics Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Therapeutics |
|
 By Source Material |
|
 By Region |
|
 Key Market Players | Eli Lilly and Company, GSK, Novartis AG, Bayer AG, AstraZeneca plc, Sanofi, Merck KGaA, Biologicals SA, Becton, Dickinson and Company, Pfizer Inc, F. Hoffmann La Roche AG |
Loading Table Of Content...
